Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA OKs Novartis’ Exelon Patch for Severe Alzheimer’s

Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer’s disease Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer’s; 24-week study showed statistically significant improvement in overall cognition and function compared to 4.6 mg/24h dose Exelon Patch first and only transdermal therapy approved to treat […]

Read More »

2nd Annual Review: CNS/Neurology 2013

Click to download the PDF to view the full issue CNS Neurology Awaiting Approval (Excel Document) New Alzheimer’s disease treatments for presymptomatic patients will increase the Ad market size in the years ahead; the multiple sclerosis segment is undergoing a strong growth phase based on the arrival of promising molecules with disease-modifying characteristics and novel […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom